Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket

Shares of Tempest Therapeutics Inc (NASDAQ: TPST) rose sharply in pre-market trading after the California-based clinical-stage biotechnology company announced an exclusive option agreement with Hebei Senlang Biotechnology Co., Ltd.

According to the announcement, the agreement gives Tempest an exclusive option to license Senlang’s CD7-targeted lentiviral vector platform and its in vivo CAR-T pipeline, including a BCMA/GPRC5D dual-targeting candidate in Phase 1 trials for relapsed or refractory multiple myeloma.

Tempest Therapeutics shares jumped 49.6% to $1.13 in pre-market trading.